What is advanced prostate cancer? Prostate cancer experts Drs. Jeri Kim and Sumit K. Subudhi, from MD Anderson Cancer Center, explain what it means to have advanced disease and how—and where in the body–the disease typically progresses. Sponsored by the Patient Empowerment Network through an educational grant from Sanofi and an...
Read More
In a nutshell The authors determined how nerve-sparing surgical techniques can improve long-term continence levels after prostate surgery. Some background Prostate surgery is a common treatment in prostate cancer that involves surgically removing the prostate gland. Different surgical techniques can be used during surgery with different...
Read More
In a nutshell The authors aimed to determine the effectiveness and safety adding bevacizumab (Avastin) to a chemotherapy regimen in previously treated patients with metastatic (spread to other areas of the body) breast cancer. Some background Metastasis is the spread of cancer to other organs in the body. Patients with metastatic...
Read More
Latest Technology Analyzes Disease Progression from Patient Power on Vimeo. Recorded on March 28, 2015 Mark Gimbel, MD Surgical Oncologist Banner MD Anderson Cancer Center Michael Wong, MD, PhD Head – Solid Tumors Section, Skin Cancer and Melanoma Clinics USC Norris Comprehensive Cancer Center Carol...
Read More
In a nutshell The authors aimed to determine the effect of two genes – ERG and PTEN – as markers in prostate cancer progression. Some background Prostate surgery is a common treatment in prostate cancer. It involves surgically removing the prostate gland. The ERG gene is a cancer gene that contains a protein...
Read More
In a nutshell The authors analyzed the effectiveness of ipilimumab (Yervoy) combined with fotemustine (Muphoran) in advanced melanoma patients. Some background In advanced melanoma (stage III/IV), cancer spreads rapidly from the skin to other parts of the body. This is known as...
Read More
In a nutshell The authors aimed to determine the effectiveness of targeted treatments and also compared combination therapies. Some background HER2 positive breast cancer is associated with the over-expression (production) of the human epidermal growth factor receptor 2 (HER2+). HER2+ breast cancer is known to be more aggressive with a poorer...
Read More
In a nutshell The authors aimed to give specific breast cancer treatment guidelines determined by medical experts. Some background The St. Gallen International Breast Cancer Conference is held every two years. Leading experts in breast cancer research meet at this conference to determine the most up-to-date guidelines for treatment. The 2015...
Read More
In a nutshell The authors evaluated the factors responsible for long-term survival in advanced melanoma. Some background In advanced melanoma (stage III/IV) cancer spreads from the skin to other parts of the body (metastasis). Less than 2% of advanced melanoma patients survive longer than 5 years following treatment. The median (midpoint)...
Read More
In a nutshell This study looked at whether the original location of tumors which have spread can predict how the cancer may progress. Some background Despite many advances in the field of colorectal cancer, relatively few markers have been found which help predict patient survival. Some factors, such as whether there is a mutation (abnormality) in...
Read More
In a nutshell This review looked at the effectiveness and safety of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, afatinib (Gilotrif) in patients with non-small cell lung cancer (NSCLC) that has spread from its original site. Some background Many NSCLC patients have a mutated (abnormal) EGFR gene, which can increase...
Read More
In a nutshell This study looked at a new drug, gefitinib (Iressa), used for treating non-small cell lung cancer (NSCLC) that has spread from its original site. Some background A common treatment option for non-small cell lung cancer is chemotherapy. Many patients find the side effects of this treatment to be quite severe. The long-term outcomes...
Read More
